Biotech China 2014

View Profile


Peer Reviewed Papers, Books, Chapters

Year Title Citation Authors
1. 2010 Variations Among Experienced Surgeons in Cancer Control After Open Radical Prostatectomy J Urol. 2010 Jan 16
2. 2009 Evaluation of molecular forms of prostate-specific antigen and human kallikrein 2 in predicting biochemical failure after radical prostatectomy. Int J Cancer. 2009 Feb 1;124(3):659-63
3. 2009 Evaluation of molecular forms of prostate-specific antigen and human kallikrein 2 in predicting biochemical failure after radical prostatectomy. Int J Cancer. 2009; 1;124(3):659-63
4. 2009 Is it necessary to remove the seminal vesicles completely at radical prostatectomy? Decision curve analysis of European Society of Urologic Oncology criteria. J Urol. 2009;181(2):609-13
5. 2009 Outcomes after radical prostatectomy in men receiving previous pelvic radiation for non-prostate malignancies. BJU Int. 2009 Feb 23
6. 2009 Circulating prostate tumor cells detected by reverse transcription-PCR in men with localized or castration-refractory prostate cancer: concordance with CellSearch assay and association with bone metastases and with survival. Clin Chem. 2009 Apr;55(4):765-73. Epub 2009 Feb 20
7. 2009 Words of wisdom. Re: Prostate cancer-specific survival following salvage radiotherapy versus observation in men with biochemical recurrence after radical prostatectomy. Trock BJ, Han M, Freedland SJ, Humphreys EB, DeWeese TL, Partin AW, Walsh PC. JAMA 2008;299:2760-9. Eur Urol. 2009 Jan;55(1):247
8. 2009 A multi-institutional evaluation of active surveillance for low risk prostate cancer J Urol. 2009 Apr;181(4):1635-41; discussion 1641. Epub 2009 Feb 23
9. 2009 Comprehensive Standardized Report of Complications of Retropubic and Laparoscopic Radical Prostatectomy Eur Urol. 2009 Nov 27.
10. 2009 A Critical Analysis of the Current Knowledge of Surgical Anatomy Related to Optimization of Cancer Control and Preservation of Continence and Erection in Candidates for Radical Prostatectomy Eur Urol. 2009 Nov 11
11. 2009 Magnetic resonance imaging in the prediction of biochemical recurrence of prostate cancer after radical prostatectomy BJU Int. 2009 Feb 11
12. 2009 TMPRSS2-ERG gene fusion is not associated with outcome in patients treated by prostatectomy Cancer Res. 2009 Feb 15;69(4):1400-6. Epub 2009 Feb 3
13. 2009 Other biomarkers for detecting prostate cancer. BJU Int. 2010 Jan;105(2):166-9. Epub 2009 Nov 20
14. 2009 Clinical stage T1c prostate cancer: evaluation with endorectal MR imaging and MR spectroscopic imaging Radiology. 2009 Nov;253(2):425-34
15. 2009 Prostatic specific antigen for prostate cancer detection. Int Braz J Urol. 2009 Sep-Oct;35(5):521-9; discussion 530-2.
16. 2009 Chronology of Erectile Function in Patients with Early Functional Erections Following Radical Prostatectomy J Sex Med. 2009 Sep 30
17. 2009 Biochemical recurrence rate in patients with positive surgical margins at radical prostatectomy with further negative resected tissue BJU Int. 2009 Sep;104(5):605-10.
18. 2009 Predictors of Recovery of Erectile Function after Unilateral Cavernous Nerve Graft Reconstruction at Radical Retropubic Prostatectomy J Sex Med. 2009 Aug 4
19. 2009 Location, Extent and Number of Positive Surgical Margins Do Not Improve Accuracy of Predicting Prostate Cancer Recurrence After Radical Prostatectomy J Urol. 2009 Aug 13
20. 2009 Preoperative and postoperative nomograms incorporating surgeon experience for clinically localized prostate cancer Cancer. 2009 Mar 1;115(5):1005-10
21. 2009 Prostatic Transition Zone Directed Needle Biopsies Uncommonly Sample Clinically Relevant Transition Zone Tumors J Urol. 2009 Aug 13
22. 2009 Prostate Cancer-Specific Mortality After Radical Prostatectomy for Patients Treated in the Prostate-Specific Antigen Era J Clin Oncol. 2009 Jul 27.
23. 2009 . Long-term follow-up of 3-month neoadjuvant hormone therapy before radical prostatectomy in a randomized trial BJU Int. 2009 Jul 8
24. 2009 Do high-volume hospitals and surgeons provide better care in urologic oncology? Urol Oncol. 2009 Jul-Aug;27(4):417-21
25. 2009 Pretreatment prostate-specific antigen (PSA) velocity and doubling time are associated with outcome but neither improves prediction of outcome beyond pretreatment PSA alone in patients treated with radical prostatectomy. J Clin Oncol. 2009 Aug 1; 27(22): 3591-7. Epub 2009 Jun 8
26. 2009 Impact of ethnicity on surgical margins at radical prostatectomy BJU Int. 2009 Apr 15
27. 2009 Critical appraisal of outcomes following open radical prostatectomy Curr Opin Urol. 2009 May;19(3):297-302.
28. 2009 Critical elements in fellowship training. Urol Oncol. 2009 Mar-Apr;27(2):199-204
29. 2009 Is it necessary to remove the seminal vesicles completely at radical prostatectomy? decision curve analysis of European Society of Urologic Oncology criteria J Urol. 2009 Feb;181(2):609-13; discussion 614. Epub 2008 Dec 13
30. 2009 Comparison of observed biochemical recurrence-free survival in patients with low PSA values undergoing radical prostatectomy and predictions of preoperative nomogram Urology. 2009 May;73(5):1098-103. Epub 2009 Mar 17.
31. 2008 Prostate-specific antigen at or before age 50 as a predictor of advanced prostate cancer diagnosed up to 25 years later: a case-control study BMC Med. 2008 Feb 15;6:6
32. 2008 Radical prostatectomy in men aged >or=70 years: effect of age on upgrading, upstaging, and the accuracy of a preoperative nomogram BJU Int. 2008 Mar;101(5):541-6
33. 2008 Effects of pathologic stage on the learning curve for radical prostatectomy: evidence that recurrence in organ-confined cancer is largely related to inadequate surgical technique Eur Urol. 2008 May;53(5):960-6. Epub 2008 Jan 14
34. 2008 Editorial comment on: first analysis of the long-term results with transrectal HIFU in patients with localized prostate cancer. Eur Urol. 2008 Jun;53(6):1202-3. Epub 2007 Nov 5.
35. 2008 Secondary therapy, metastatic progression, and cancer-specific mortality in men with clinically high-risk prostate cancer treated with radical prostatectomy. Eur Urol. 2008 May;53(5):950-9. Epub 2007 Oct 12
36. 2008 Local progression among men with conservatively treated localized prostate cancer: results from the Transatlantic Prostate Group Eur Urol. 2008 Feb;53(2):347-54. Epub 2007 May 30
37. 2008 Modified technique for neurovascular bundle preservation during radical prostatectomy: association between technique and recovery of erectile function BJU Int. 2008 May;101(10):1217-22. Epub 2008 Feb 15
38. 2008 Effects of Pathologic Stage on the Learning Curve for Radical Prostatectomy: Evidence That Recurrence in Organ-Confined Cancer Is Largely Related to Inadequate Surgical Technique Eur Urol. 2008; 53(5):960-6
39. 2008 Radical prostatectomy in men aged >or=70 years: effect of age on upgrading, upstaging, and the accuracy of a preoperative nomogram BJU Int. 2008; 101(5):541-6
40. 2008 Modified technique for neurovascular bundle preservation during radical prostatectomy: association between technique and recovery of erectile function BJU Int. 2008; 101(10):1217-22
41. 2008 Prostate-specific antigen at or before age 50 as a predictor of advanced prostate cancer diagnosed up to 25 years later: a case-control study BMC Med. 2008; 26(6):835-41
42. 2008 Long-term prediction of prostate cancer: prostate-specific antigen (PSA) velocity is predictive but does not improve the predictive accuracy of a single PSA measurement 15 years or more before cancer diagnosis in a large, representative, unscreened population. J Clin Oncol. 2008; 20;26(6):835-41
43. 2008 Impact of Socioeconomic Factors on Prostate Cancer Outcomes in Black Patients Treated with Surgery Urology. 2008; [Epub ahead of print]
44. 2008 Radical prostatectomy for high-risk prostate cancer World J Urol. 2008; 26(3):219-24
45. 2008 Comprehensive prospective comparative analysis of outcomes between open and laparoscopic radical prostatectomy conducted in 2003 to 2005. J Urol. 2008 May;179(5):1811-7; discussion 1817
46. 2008 Comparison of stage migration patterns between Europe and the USA: an analysis of 11 350 men treated with radical prostatectomy for prostate cancer BJU Int. 2008; 101(12):1513-8
47. 2008 Predicting an Optimal Outcome After Radical Prostatectomy: The Trifecta Nomogram J Urol. 2008; 179(6):2207-10
48. 2008 Surgeon Experience is Strongly Associated With Biochemical Recurrence After Radical Prostatectomy for All Preoperative Risk Categories J Urol. 2008; 179(6):2212-6; discussion 2216-7
49. 2008 The role of SPINK1 in ETS rearrangement-negative prostate cancers Cancer Cell. 2008;13(6):519-28
50. 2008 Oncologic Outcome and Patterns of Recurrence after Salvage Radical Prostatectomy. Eur Urol. 2008 Jul 14. [Epub ahead of print]
51. 2008 Robotic-Assisted Prostatectomy: Is There Truth in Advertising? Eur Urol. 2008; 54(4):720-2
52. 2008 Role of radical prostatectomy in the treatment of high-risk prostate cancer Curr Urol Rep. 2008; 9(3): 203-10
53. 2008 Pathological Upgrading and Up Staging With Immediate Repeat Biopsy in Patients Eligible for Active Surveillance J Urol. 2008; 180(5):1964-7
54. 2008 Positive Surgical Margins in Radical Prostatectomy: Outlining the Problem and Its Long-Term Consequences Eur Urol. 2008 Oct 1. [Epub ahead of print]
55. 2008 Positive Surgical Margins in Radical Prostatectomy: Outlining the Problem and Its Long-Term Consequences Eur Urol. 2008 Oct 1.
56. 2008 Pathological upgrading and up staging with immediate repeat biopsy in patients eligible for active surveillance J Urol. 2008 Nov;180(5):1964-7; discussion 1967-8. Epub 2008 Sep 17.
57. 2008 Role of radical prostatectomy in the treatment of high-risk prostate cancer Curr Urol Rep. 2008 May;9(3):203-10
58. 2008 Robotic-assisted prostatectomy: is there truth in advertising? Eur Urol. 2008 Oct;54(4):720-2. Epub 2008 Jul 21.
59. 2008 Oncologic Outcome and Patterns of Recurrence after Salvage Radical Prostatectomy Eur Urol. 2008 Jul 14
60. 2008 The role of SPINK1 in ETS rearrangement-negative prostate cancers PMID: 18538735
61. 2008 Do margins matter? The prognostic significance of positive surgical margins in radical prostatectomy specimens J Urol. 2008 May;179(5 Suppl):S47-51
62. 2008 Surgeon experience is strongly associated with biochemical recurrence after radical prostatectomy for all preoperative risk categories J Urol. 2008 Jun;179(6):2212-6; discussion 2216-7. Epub 2008 Apr 18
63. 2008 Predicting an optimal outcome after radical prostatectomy: the trifecta nomogram. J Urol. 2008 Jun;179(6):2207-10; discussion 2210-1. Epub 2008 Apr 18
64. 2008 Comprehensive prospective comparative analysis of outcomes between open and laparoscopic radical prostatectomy conducted in 2003 to 2005. J Urol. 2008 May;179(5):1811-7; discussion 1817. Epub 2008 Mar 18
65. 2008 Radical prostatectomy for high-risk prostate cancer World J Urol. 2008 Jun;26(3):219-24. Epub 2008 Mar 12.
66. 2008 Long-term prediction of prostate cancer: prostate-specific antigen (PSA) velocity is predictive but does not improve the predictive accuracy of a single PSA measurement 15 years or more before cancer diagnosis in a large, representative, unscreened population J Clin Oncol. 2008 Feb 20;26(6):835-41
67. 2007 Association of cysteine-rich secretory protein 3 and beta-microseminoprotein with outcome after radical prostatectomy. Clin Cancer Res. 2007; 13(14):4130-8
68. 2007 Estrogenic side effects of androgen deprivation therapy Rev Urol. 2007 Fall;9(4):163-80.
69. 2007 Prognostic significance of location of positive margins in radical prostatectomy specimens Urology. 2007 Nov;70(5):965-9
70. 2007 B7-H3 and B7x are highly expressed in human prostate cancer and associated with disease spread and poor outcome Proc Natl Acad Sci U S A. 2007 Dec 4;104(49):19458-63. Epub 2007 Nov 27
71. 2007 Surgery Insight: optimizing open nerve-sparing radical prostatectomy techniques for improved outcomes Nat Clin Pract Urol. 2007 Oct;4(10):561-9
72. 2007 Radical prostatectomy for clinical T3 disease: expanding indications while optimizing cancer control and quality of life Nat Clin Pract Urol. 2007 Aug;4(8):451-4
73. 2007 The predictive value of prostate cancer biomarkers depends on age and time to diagnosis: towards a biologically-based screening strategy Int J Cancer. 2007 Nov 15;121(10):2212-7
74. 2007 The surgical learning curve for prostate cancer control after radical prostatectomy. J Natl Cancer Inst. 2007 Aug 1;99(15):1171-7. Epub 2007 Jul 24
75. 2007 Association of cysteine-rich secretory protein 3 and beta-microseminoprotein with outcome after radical prostatectomy Clin Cancer Res. 2007 Jul 15;13(14):4130-8.
76. 2007 Radical prostatectomy shortly after prostate biopsy does not affect operative difficulty or efficacy Urology. 2007 Jun;69(6):1128-33
77. 2007 Radical prostatectomy for clinically localized, high risk prostate cancer: critical analysis of risk assessment methods J Urol. 2007 Aug;178(2):493-9; discussion 499. Epub 2007 Jun 11
78. 2007 Standard versus limited pelvic lymph node dissection for prostate cancer in patients with a predicted probability of nodal metastasis greater than 1%. J Urol. 2007 Jul;178(1):120-4. Epub 2007 May 11
79. 2007 Locally ablative therapies for primary radiation failures: a review and critical assessment of the efficacy Curr Urol Rep. 2007 May;8(3):217-23
80. 2007 The anatomical and pathological characteristics of irradiated prostate cancers may influence the oncological efficacy of salvage ablative therapies J Urol. 2007 Apr;177(4):1324-9; quiz 1591
81. 2007 Does neurovascular bundle preservation at the time of radical prostatectomy improve urinary continence? Nat Clin Pract Urol. 2007 Mar;4(3):138-9. Epub 2007 Feb 13.
82. 2007 Free PSA isoforms and intact and cleaved forms of urokinase plasminogen activator receptor in serum improve selection of patients for prostate cancer biopsy Int J Cancer. 2007 Apr 1;120(7):1499-504
83. 2007 Risk-adjusted analysis of positive surgical margins following laparoscopic and retropubic radical prostatectomy Eur Urol. 2007 Oct;52(4):1090-6. Epub 2006 Dec 13.
84. 2007 Comparison of free and total forms of serum human kallikrein 2 and prostate-specific antigen for prediction of locally advanced and recurrent prostate cancer Clin Chem. 2007 Feb;53(2):233-40. Epub 2006 Dec 21
85. 2007 Bone health in men receiving androgen deprivation therapy for prostate cancer J Urol. 2007 Jan;177(1):17-24. Review.
86. 2007 Expectant management of prostate cancer Kavoussi LR, Novick AC, Partin AW, Wein AJ, eds. Campbell’s Urology. 9th ed. Philadelphia: W B. Saunders Company, 2007
87. 2007 Estrogenic side effects of androgen deprivation therapy Rev Urol. 2007;9(4):163-80
88. 2007 Prognostic significance of location of positive margins in radical prostatectomy specimens Urology. 2007;70(5):965-9
89. 2007 Secondary Therapy, Metastatic Progression, and Cancer-Specific Mortality in Men with Clinically High-Risk Prostate Cancer Treated with Radical Prostatectomy Eur Urol. 2007; 53(5):950-9
90. 2007 Major shifts in the treatment and prognosis of prostate cancer due to changes in pathological diagnosis and grading BJU Int. 2007;100(6):1240-4
91. 2007 Editorial Comment on: First Analysis of the Long-Term Results with Transrectal HIFU in Patients with Localized Prostate Cancer Eur Urol. 2007; 53(6):1202-3
92. 2007 Nomogram incorporating PSA level to predict cancer-specific survival for men with clinically localized prostate cancer managed without curative intent Cancer. 2007; 112(1):69-74
93. 2007 B7-H3 and B7x are highly expressed in human prostate cancer and associated with disease spread and poor outcome Proc Natl Acad Sci U S A. 2007; 104(49):19458-63
94. 2007 Surgery Insight: optimizing open nerve-sparing radical prostatectomy techniques for improved outcomes Nat Clin Pract Urol. 2007; 4(10):561-569
95. 2007 Pitfalls in the diagnosis of prostatic cancer: retrospective review of 1791 cases with clinical outcome. Histopathology. 2007; 51(4):452-457
96. 2007 Surgery for progression after failed radiation therapy Eur J Cancer 2007; 5 (5):189-198
97. 2007 Clinically significant prostate cancer local recurrence after radiation therapy occurs at the site of primary tumor: magnetic resonance imaging and step-section pathology evidence. Int J Radiat Oncol Biol Phys. 2007; 69(1):62-9
98. 2007 Prostate cancer. Clinical practice guidelines in oncology J Natl Compr Canc Netw. 2007 ;5(7):650-83
99. 2007 Radical prostatectomy for clinical T3 disease: expanding indications while optimizing cancer control and quality of life Nat Clin Pract Urol. 2007; 4(8):451-4.
100. 2007 The surgical learning curve for prostate cancer control after radical prostatectomy. J Natl Cancer Inst. 2007; 99(15):1171-7
101. 2007 The predictive value of prostate cancer biomarkers depends on age and time to diagnosis: Towards a biologically-based screening strategy Int J Cancer. 2007; [Epub ahead of print]
102. 2007 Radical Prostatectomy for Clinically Localized, High Risk Prostate Cancer: Critical Analysis of Risk Assessment Methods J Urol. 2007; 178(2):493-9
103. 2007 Radical prostatectomy shortly after prostate biopsy does not affect operative difficulty or efficacy Urology, 2007; 69(6):1128-33
104. 2007 Standard vs Limited Pelvic Lymph Node Dissection for Prostate Cancer in Patients With a Predicted Probability of Nodal Metastasis Greater Than 1%. J Urol. 2007; [Epub ahead of print]
105. 2007 Local Progression among Men with Conservatively Treated Localized Prostate Cancer: Results from the Transatlantic Prostate Group Eur Urol. 2007 May 30; [Epub ahead of print]
106. 2007 Radical Prostatectomy for Clinically Localized, High Risk Prostate Cancer: Critical Analysis of Risk Assessment Methods J Urol. 2007 Jun 8; [Epub ahead of print]
107. 2007 Bilateral cavernous nerve interposition grafting during radical retropubic prostatectomy: Memorial Sloan-Kettering Cancer Center experience J Urol. 2007; 177(2):664-8
108. 2007 Does neurovascular bundle preservation at the time of radical prostatectomy improve urinary continence? Nat Clin Pract Urol. 2007; 4(3):138-9
109. 2007 The anatomical and pathological characteristics of irradiated prostate cancers may influence the oncological efficacy of salvage ablative therapies Urol. 2007; 177(4):1324-9
110. 2007 Locally ablative therapies for primary radiation failures: a review and critical assessment of the efficacy Curr Urol Rep. 2007; 8(3):217-23
111. 2007 Free PSA isoforms and intact and cleaved forms of urokinase plasminogen activator receptor in serum improve selection of patients for prostate cancer biopsy Int J Cancer 2007; epub
112. 2007 Bone health in men receiving androgen deprivation therapy for prostate cancer. J Urol 2007; 177:17-24
113. 2006 Poorly differentiated prostate cancer treated with radical prostatectomy: long-term outcome and incidence of pathological downgrading J Urol. 2006; 176:991-5.
114. 2006 The natural history of metastatic prostate cancer after radical prostatectomy Eur Urol 2006; epub.
115. 2006 The clinical features of anterior prostate cancers BJU Int 2006; 98:1167-1171.
116. 2006 Risk-adjusted analysis of positive surgical margins following laparoscopic and retropubic radical prostatectomy Eur Urol 2006; epub
117. 2006 Comparison of free and total forms of serum human kallikrein 2 and prostate-specific antigen for prediction of locally advanced and recurrent prostate cancer Clin Chem 2006; epub
118. 2006 Salvage radical prostatectomy for recurrence of prostate cancer after radiation therapy Vogelzang NJ, Scardino PT, Shipley WU, DF Coffey, eds. Comprehensive Textbook of Genitourinary Oncology. 3rd ed. Baltimore: Lippincott Williams and Wilkins, 2006:306-314
119. 2006 Prostate cancer diagnosed after repeat biopsies have a favorable pathological outcome but similar recurrence rate J Urol 2006; 175:923-7
120. 2006 Rationale for zoledronic acid therapy in men with hormone-sensitive prostate cancer with or without bone metastasis Urol Oncol 2006; 24:4-12
121. 2006 Endorectal MR imaging before salvage prostatectomy: tumor localization and staging Radiology 2006; 238:176-83
122. 2006 Does a delay between diagnosis and radical prostatectomy increase the risk of disease recurrence? Cancer 2006; 106:576-80
123. 2006 Risk assessment for biochemical recurrence prior to radical prostatectomy: significant enhancement contributed by human glandular kallikrein 2 (hK2) and free prostate specific antigen (PSA) in men with moderate PSA-elevation in serum Int J Cancer 2006; 118:1234-40
124. 2006 Cancer-specific survival and predictors of prostate-specific antigen recurrence and survival in patients with seminal vesicle invasion after radical prostatectomy Cancer 2006;106:2369-75
125. 2006 The association between total and positive lymph node counts, and disease progression in clinically localized prostate cancer J Urol 2006; 175:1320-4.
126. 2006 Long-term outcome following radical prostatectomy in men with clinical stage T3 prostate cancer J Urol 2006;176:564-8
127. 2006 Favorable clinical outcomes of three-dimensional computer-optimized high-dose-rate prostate brachytherapy in the management of localized prostate cancer Brachytherapy 2006; 5:157-64.
128. 2006 Radical prostatectomy in patients infected with human immunodeficiency virus. BJU Int 2006; 98:303-7
129. 2006 Nerve-sparing radical retropubic prostatectomy Atlas of the Prostate. 3rd ed. Philadelphia: Current Medicine LLC, 2006:145-16
130. 2006 Preservation of sexual function after treatment for prostate cancer Kirby RS, Partin AW, Feneley M, Parsons JK, eds. Prostate Cancer: Principles and Practice. Abington, United Kingdom: Taylor & Francis, 2006: 675-682
131. 2006 African-American race is a predictor of prostate cancer detection: incorporation into a pre-biopsy nomogram BJU Int 2006; 98:783-7
132. 2006 Defining biochemical recurrence of prostate cancer after radical prostatectomy: a proposal for a standardized definition J Clin Oncol. 2006; 24:3973-8
133. 2005 Gleason grade remains an important prognostic predictor in men diagnosed with prostate cancer while on finasteride therapy BJU Int 2005; 95:509-512
134. 2005 Active surveillance for prostate cancer with selective delayed definitive therapy Clin Prostate Cancer 2005; 4:45-49
135. 2005 Early-stage, aggressive prostate cancer in a nonelderly patient with no comorbidities Clinical Care Options Oncology 2005:1-7
136. 2005 Radical prostatectomy for clinical stage T1 and T2 prostate cancer. Vogelzang NJ, Scardino PT, Shipley WU, DF Coffey, eds. Comprehensive Textbook of Genitourinary Oncology. 3rd ed. Baltimore: Lippincott Williams and Wilkins, 2005:166-189
137. 2005 Book review: Prostate Cancer: Science and Clinical Practice Urology 2005; 65:213
138. 2005 The pattern of PSA failure dictates the probability of a positive bone scan in patients with a rising PSA after radical prostatectomy. J Clin Oncol 2005; 23:1962-1968
139. 2005 Long-term oncologic results of salvage radical prostatectomy for locally recurrent prostate cancer after radiotherapy Int J Radiat Oncol Biol Phys 2005; 62:448-453
140. 2005 Postoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy J Clin Oncol 2005; 23:7005-7012
141. 2005 Achieving optimal outcomes after radical prostatectomy J Clin Oncol 2005; 23:4146-4151
142. 2005 Pattern of prostate-specific antigen (PSA) failure dictates the probability of a positive bone scan in patients with an increasing PSA after radical prostatectomy. J Clin Oncol 2005; 23:1962-1968
143. 2005 Prognostic impact of positive surgical margins in surgically treated prostate cancer: multi-institutional assessment of 5831 patients Urology 2005; 66:1245-50
144. 2005 Is intraoperative frozen section analysis an efficient way to reduce positive surgical margins? Urology 2005; 66:1287-91
145. 2005 Prostate-specific antigen doubling time as a prognostic marker in prostate cancer. Nat Clin Pract Urol 2005: 10:482-91.
146. 2005 Role of salvage prostatectomy for recurrent prostate cancer after radiation therapy. J Clin Oncol 2005; 23:8198-8203
147. 2005 Radical prostatectomy: long-term cancer control and recovery of sexual and urinary function (“trifecta”) Urology 2005; 66:83-94.
148. 2005 Do margins matter? The prognostic significance of positive surgical margins in radical prostatectomy specimens J Urol 2005; 174:903-907
149. 2005 Does the time from biopsy to surgery affect biochemical recurrence after radical prostatectomy? BJU Int 2005; 96:773-776
150. 2005 Testosterone as a predictor of pathological stage in clinically localized prostate cancer J Urol 2005; 173:1935-1937
151. 2005 Recovery of erectile function after salvage radical prostatectomy for locally recurrent prostate cancer after radiotherapy Urology 2005; 66:623-626
152. 2004 Pelvic lymphadenectomy at the time of radical prostatectomy: is it beneficial? Urologic Oncology: Seminars and Original Investigations 2004; 22:2002.
153. 2004 CALGB trial 90203: randomized phase III study of radical prostatectomy alone versus docetaxel prior to radical prostatectomy for patients with high-risk localized prostate cancer AJUR 2004; 2:33
154. 2004 Salvage radical prostatectomy: improving outcome after failed radiation therapy Cont Urol 2004; 14:34
155. 2004 Bisphosphonates and prostate cancer: maintaining bone integrity and quality of life AJUR 2004; 2:5
156. 2004 Gleason score and pretreatment prostate-specific antigen in survival among patients with stage D2 prostate cancer World J Urol 2004; 22:425-430. Epub 2004 Dec 08.
157. 2004 Commentary. Skeletal fractures negatively correlate with overall survival in men with prostate cancer AJUR 2004; 2:21.
158. 2004 Salvage therapy for locally recurrent prostate cancer after external beam radiotherapy Curr Treat Options Oncol 2004; 5:357-365.
159. 2004 Anatomic radical prostatectomy in the management of localized prostate cancer Cummings KB, eds. Management of Prostate Cancer: Advances and Controversies. New York: Marcel Dekker, 2004:1-54
160. 2004 Review of Comparing radical prostatectomy and brachytherapy for localized prostate cancer Quaranta BP, Marks LB, Anscher MS. Oncology 2004; 18:1304-1309
161. 2004 Commentary. Treatment options for stage T1-T2 prostate cancer. AJUR 2004; 2:507
162. 2004 Current recommendations for delaying renal transplantation after localized prostate cancer treatment: are they still appropriate? Transplantation. 2004;78:710-712
163. 2004 Race is not predictor of prostate cancer detection on repeat prostate biopsy J Urol 2004; 172:1853-1855
164. 2004 Morbidity and functional outcomes of salvage radical prostatectomy for locally recurrent prostate cancer after radiation therapy J Urol 2004; 172:2239-2243
165. 2004 Cancer treatment-induced bone loss (CTIBL) in prostate cancer: Pathophysiology, preclinical findings, and treatment with zoledronic acid Eur Urol Suppl 2004
166. 2004 Is year of radical prostatectomy a predictor of outcome in prostate cancer? J Urol 2004; 171:692-696
167. 2004 Feasibility of radical prostatectomy after neoadjuvant chemohormonal therapy for patients with high risk or locally advanced prostate cancer: Results of a phase I/II study J Urol 2004; 171:709-713
168. 2004 Do concerns about more advanced pathological features increase the likelihood of neurovascular bundle resection in African-American men undergoing radical prostatectomy? J Urol 2004; 171:700-702
169. 2004 Multimodal treatment strategies in high-risk localized prostate cancer AJUR 2004; 2:50
170. 2003 Variations among individual surgeons in the rate of positive surgical margins in radical prostatectomy specimens J Urol, 2003; 170:2292-2295
171. 2003 Cancer and Leukemia Group B (CALGB) 90203: a randomized phase 3 study of radical prostatectomy alone versus estramustine and docetaxel before radical prostatectomy for patients with high-risk localized disease. Urology 2003; 62:55.
172. 2003 Counseling men with prostate cancer: nomogram for predicting presence of small, moderately differentiated, confined tumors J Urol 2003; 170:1792-1797
173. 2003 . A preoperative nomogram identifying decreased risk of positive pelvic lymph nodes in patients with prostate cancer J Urol 2003; 170:1798-1803
174. 2003 Dietary manipulation, ethnicity, and serum prostate specific antigen levels Urology 2003; 62:677-682
175. 2003 Genotype-phenotype analysis for the polymorphic CA repeat in the insulin-like growth factor-I (IGF-I) gene. Eur J Epidemiol 2003; 18:203-209
176. 2003 Variation of serum prostate specific antigen levels: an evaluation of year-to-year fluctuations in a well defined cohort of men JAMA. 2003; 289:2695-2700
177. 2003 Algorithms for PSA recurrence after treatment of localized prostate cancer Clinical Prostate Cancer 2003; 1:221-226
178. 2003 Age and PSA Predict The Likelihood Of Organ-Confined Disease In Men Presenting With PSA < 10 Ng/Ml: Implications For Screening Urology 2003; 62:70-74
179. 2003 Zoledronic acid increases bone mineral density in men receiving androgen deprivation therapy for nonmetastatic prostate cancer J Urol 2003; 169:2008-2012
180. 2003 Update on nerve grafting during radical prostatectomy AUA News 2003; 8:40-41
181. 2003 High-risk localized prostate cancer: multimodal treatment strategies combining neoadjuvant hormonal therapy and/or chemotherapy with radical prostatectomy Expert Opin Emerging Drugs, 2003; 8:291
182. 2003 Salvage radical prostatectomy for recurrence of prostate cancer after radiation therapy. Current Urology Reports 2003; 4:211
183. 2003 Bisphosphonates and prostate cancer AUA News 2003; 8:44-46
184. 2003 Salvage radical prostatectomy for recurrence of prostate cancer after radiation therapy Curr Urol Rep 2003; 4:211
185. 2003 How stable are serum PSA levels? Journal Watch, Audio 2003; 14:15
186. 2002 Prostate biopsy techniques and indications: when, where, and how? Semin Urol Oncol 2002; 20:108-115
187. 2002 Clinical stage T1c prostate cancer: pathologic outcomes following radical prostatectomy in black and white men Prostate 2002; 50:236-240
188. 2002 International validation of a preoperative nomogram for prostate cancer recurrence following radical prostatectomy J Clin Oncol 2002; 20:3206-3212
189. 2002 Squamous cell carcinoma of the penis: a retrospective review of forty-five patients in Northwest Louisiana South Med J. 2002; 95:822-825
190. 2002 Nomograms as predictive models Semin Urol Oncol 2002; 20:108-115
191. 2002 Analysis of clinical stage T2 prostate cancer: do current subclassifications represent an improvement? J Clin Oncol 2002; 20:2025-2030
192. 2002 Treatment of chronic prostatitis lowers serum prostate specific antigen J Urol 2002; 167:1723-1726
193. 2002 Large granular cell tumor of the penis in a 53-year-old man with coexisting prostate cancer Urology 2002; 59:602
194. 2001 Preoperative autologous blood donation in radical retropubic prostatectomy: a cost-effectiveness analysis Int J Healthcare Technology and Management 2001; 3:322-336
195. 2001 Renal cell carcinoma detected in a cadaveric donor after orthotopic liver and contralateral renal transplant in two recipients. Transplantation 2001; 71:1348-1349
196. 2001 Racial variation in prostate specific antigen in a large cohort of men without prostate cancer J La State Med Soc 2001; 153:184-189
197. 2001 Radical prostatectomy Walsh PC, Retik AB, Vaughn Jr ED, Wein AJ, eds. Campbell’s Urology. 8th ed. Philadelphia: W B. Saunders Company, 2001
198. 2001 Treatment of prostate cancer: surgery DeVita VT, Hellman S, Rosenberg SA, eds. Progress in Oncology, 2001. Boston: Jones and Bartlett, 2001:278-312
199. 2001 Early diagnosis and treatment of prostate cancer Dis Mon 2001;47:421
200. 2000 Tensile strength of cadaveric fascia lata compared to small intestinal submucosa using suture pull through analysis J Urol 2000;165:486-490.
201. 2000 Radical prostatectomy for clinical stage T1 and T2 prostate cancer Vogelzang NJ, Scardino PT, Shipley WU, DF Coffey, eds. Comprehensive Textbook of Genitourinary Oncology. 2nd ed. Baltimore: Lippincott Williams and Wilkins, 2000:722-738
202. 2000 Disease recurrence in African-American and white men undergoing radical prostatectomy for clinical stage T1-T2 prostate cancer J Urol 2000; 163:143-145
203. 2000 Undifferentiated sex cord/stromal testis tumor Urology 2000; 55:436
204. 2000 Suppression of primary tumor growth and the progression to metastatic disease using adenoviral-mediated p53 gene therapy in prostate cancer J Urol 2000; 164:814-819
205. 2000 Androgen receptor mutations in prostate cancer. Cancer Res 2000; 60:944-949
206. 2000 A Southwest Oncology Group Study of paclitaxal and carboplatin for advanced transitional cell carcinoma: the importance of survival as a clinical endpoint J Clin Oncol 2000; 18:2537-2544
207. 1999 Race is not an independent predictor of positive surgical margins after radical prostatectomy Urology 1999; 54:869-874
208. 1999 Amphiregulin is coordinately expressed with heparin-binding epidermal growth factor-like growth factor in the interstitial smooth muscle of human prostate Endocrinol 1999; 54:5866-5875.
209. 1999 Clinical and biopsy specimen features in African-American and white men with clinically localized prostate cancer. South Med J 1999; 93:400-402
210. 1999 Serum testosterone levels in African-American and Caucasian men undergoing prostate biopsy Urology 1999; 54:1035-1038
211. 1999 Development of a nomogram which predicts the probability of a positive prostate biopsy in men with an abnormal digital rectal examination and a prostate specific antigen between 0 and 4 ng/ml Urology 1999; 54:709-713.
212. 1999 Cloning and characterization of the prostate specific membrane antigen promoter J Cell Biochem 1999; 74(3):395-405.
213. 1999 The incidence and implications of renal cell carcinoma in cadaveric renal transplants at the time of organ recovery Transplantation 1999; 67:1438-1440
214. 1999 Renal cell carcinoma in an intrathoracic kidney: radiographic findings and surgical considerations South Med J 1999; 92:628-629
215. 1999 Progressive prostate cancer associated with use of megesterol acetate administered for control of hot flashes South Med J 1999; 92:415-416
216. 1999 Seminal vesicle abscess secondary to tuberculosis: role of tissue culture in making the diagnosis South Med J 1999; 92:328-329
217. 1999 Race is not independently associated with a positive prostate biopsy in men suspected of having prostate cancer. Urology 1999; 53:553-556
218. 1999 Androgen receptor gene CAG repeat length varies in a race-specific fashion in men without prostate cancer Urology 1999; 53:378-380
219. 1998 Penetrating trauma to the male external genitalia. J Trauma 1998; 44:492-494
220. 1998 Nilutamide response after flutamide failure in post-orchiectomy progressive prostate cancer J Urol 1998; 159:990
221. 1998 Cancers of the urinary tract Suki WN, Massry SG, eds. Suki and Massry’s Therapy of Renal Diseases and Related Disorders. 3rd ed. Boston: Kluwer Academic Publishers, 1998:695-722.
222. 1998 Radical prostatectomy Walsh PC, Retik AB, Vaughn Jr ED, Wein AJ, eds. Campbell’s Urology. 7th ed. Philadelphia: W.B. Saunders Company, 1998:2547-2564.
223. 1998 A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer J Natl Ca Inst 1998; 90:766-771
224. 1998 Clinical characteristics and biopsy specimen features in African-American and white men without prostate cancer J Natl Ca Inst 1998; 90:756-760
225. 1997 Granulomatous mass in a non-refluxing renal unit after BCG therapy for bladder cancer J Urol 1997; 158:882-883
226. 1997 Prostate specific antigen (PSA) and PSA density: racial differences in men without prostate cancer. J Natl Ca Inst 1997; 89:134-138
227. 1997 Fifteen year survival and recurrence rates after radiotherapy for prostate cancer. J Clin Oncol 1997; 15:3214-3222
228. 1997 Influence of hepatic function on serum levels of prostate specific antigen J Urol 1997; 158:1867-1869
229. 1997 Prostate cancer metastatic only to the penis South Med J 1997; 90:959-961
230. 1997 Fat density in renal cell carcinoma: demonstration with computed tomography J Urol 1997; 157:1347-1348
231. 1996 Radical prostatectomy for clinical stage T1 and T2 prostate cancer Vogelzang NJ, Scardino PT, Shipley WU, Coffey DF, eds. Comprehensive Textbook of Genitourinary Oncology. 1st ed. Baltimore: Williams and Wilkins, 1996:741-758
232. 1996 Prostate cancer gene therapy: Herpes simplex virus thymidine kinase gene transduction followed by ganciclovir in mouse and human prostate models Hum Gene Ther 1996; 7:515-523
233. 1996 Spontaneous drainage of an appendiceal abscess into an orthotopic neobladder. J Urol 1996; 155:2028
234. 1996 The use of an anti-ras ribozyme to alter the malignant phenotype of a human bladder cancer cell line J Urol 1996; 156:1186-1188
235. 1996 Testicular microlithiasis as a predictor of intratubular germ cell neoplasia. Urology 1996; 48:797-799.
236. 1996 Risk factors for urinary incontinence after radical retropubic prostatectomy J Urol 1996; 156:1707-1713
237. 1995 Loss of p53 function leads to metastasis in ras + myc-initiated mouse prostate cancer Oncogene 1995; 10:869-879
238. 1995 In vivo gene therapy with p53 or p21 adenovirus for prostate cancer. Cancer Res 1995; 55:5151-5155.
239. 1995 Impalpable prostate cancer: Clinicopathologic features Br J Urol 1995; 77:429-432
240. 1995 TGF-ß1: Comparative immunohistochemical localization in human primary and metastatic prostate cancer. Lab Invest 1995; 73:628-635
241. 1995 Eastham JA, Stapleton AMF, Gousse AE, Timme TL, Yang G, Slawin KM, Wheeler TM, Scardino PT, Thompson TC J Urol 1995; 154:2103-2109
242. 1995 Association of p53 mutations with metastatic prostate cancer. Clin Ca Res 1995; 1:1111-1118
243. 1994 Surgical resection in patients with a non-seminomatous germ cell tumor who fail to normalize their serum tumor markers after chemotherapy Urology 1994; 43:74-80
244. 1994 Management and evaluation of localized amyloidosis of the bladder Urology 1994; 44:282-284
245. 1994 Tissue and cell-cell interactions in prostate cancer progression Cancer 1994; 75:1885-1891
246. 1994 Molecular pathways in prostate carcinogenesis. In: Imai K, Shimazaki, Carr JP, eds. Fundamental approaches to the diagnosis and treatment for prostate cancer and BPH. Guilderland, NY: Adenine Press, 1994:145-149
247. 1994 Blunt renal trauma in the pediatric population: indications for radiographic evaluation. Urology 1994; 44:406-410.
248. 1994 Xanthogranulomatous pyelonephritis: clinical findings and surgical considerations Urology 1994; 43:295-299
249. 1994 Can radical prostatectomy alter the progression of poorly differentiated prostate cancer? J Urol 1994; 152:1843-1849.
250. 1993 Isolated pulmonary metastases in prostatic adenocarcinoma. West J Med 1993; 159:489-490.
251. 1993 Urological evaluation and management of renal proximity stab wounds J Urol 1993; 150:1771-1773
252. 1993 Technique of Mitomycin-C. instillation in the treatment of upper urinary tract urothelial tumors J Urol 1993; 150:324-325
253. 1992 Radiographic evaluation of the adult blunt trauma patient. J Urol 1992; 148:266-267
254. 1992 A case of simultaneous bilateral nonseminomatous testicular tumors in persistent Mullerian duct syndrome J Urol 1992; 148:407-408.
255. 1992 The surgical management of urethral stricture disease based on etiology Urology 1992; 40:110-112
256. 1992 The occurrence of urologic injuries in patients with gun shot wounds to the spine. Semin Urol 1992; X:112-114
257. 1992 Angiographic embolization of renal stab wounds. J Urol 1992;148:268-270
258. 1991 Radiographic assessment of blunt renal trauma. J Trauma 1991; 31:1527-1528


4th Annual Pharma R&D Asia Congress
About Us | Privacy Policy | Site Map | FAQs | Advertise With Us | Community
BiotechScienceNews.com promotes research and ranks life scientists working in the life science spectrum involving biotechnology,
drug discovery, genomics, microbiology, neuroscience, medicine, pharmacology, cell biology, and molecular biology.